Publications

Andersen ME, Gentry PR, Swenberg JA, Mundt KA, White KW, Thompson C, Bus J, Sherman JH, Greim H, Bolt H, Marsh GM, Checkoway H, Coggon D, Clewell HJ. 2019. Considerations for refining the risk assessment process for formaldehyde: Results from an interdisciplinary workshop. Regul Toxicol Pharmacol 106(Aug):210–223; doi: 10.1016/j.yrtph.2019.04.015.

Clewell RA, Thompson CM, Clewell HJ. 2019. Dose-dependence of chemical carcinogenicity: Biological mechanisms for thresholds and implications for risk assessment. Chem Biol Interact 301(March):112–127; doi: 10.1016/j.cbi.2019.01.025.

Chappell G, Rager J, Wolf J, Babic M, Leblanc, Ring C, Harris MA, Thompson CM. 2019. Comparison of gene expression responses in the small intestine of mice following exposure to three carcinogens using the S1500+ gene set informs a potential common adverse outcome pathway. Toxicol Pathol 47(7):851-864; doi: 10.1177/0192623319873.

van de Ligt J, Borghoff SJ, Yoon M, Ferguson LJ, DeMaio W, McClanahan RH. 2019. Nondetectable or minimal detectable residue levels of N-(n-butyl) thiophosphoric triamide in bovine tissues and milk from a 28-d NBPT dosing study. Translat An Sci 3(4)1606-1616; doi: 10.1093/tas/txz153.

Cekola P, Henrikson A, Reichert H, Cohen S, Huhmann M, Torres KA. Clinical use and safety of an amino acid-based infant formula in a real world setting. Poster at NASPGHAN, Chicago, IL, October 2019.

Bylsma LC, Dean R, Lowe K, Sangaré L, Alexander DD, Fryzek JP. 2019. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta‐analysis of patient and study characteristics. Cancer Med 8(12):5800–5809; doi: 10.1002/cam4.2413.

Hooda N, Quinn E, DeAngelis C, Pasetka M, McFarlane T. 2019. Delayed CINV in FOLFOX chemotherapy: A retrospective chart review comparing two Ontario hospitals. Poster presented at the Canadian Association for Pharmacy in Oncology Annual Conference, Halifax, NS, April 2019.

Hooda N, McFarlane T, Pasetka M, DeAngelis C. Chemotherapy-induced nausea and vomiting (CINV) in colorectal cancer (CRC) patients undergoing FOLFOX Chemotherapy: A retrospective chart review comparing two Ontario hospitals. Poster presented at the Canadian Society for Pharmaceutical Sciences Annual Conference, Vancouver, BC, May 2019.

Hooda N, Quinn E, DeAngelis C, Pasetka M, McFarlane T. 2019. Delayed CINV in FOLFOX chemotherapy: A retrospective chart review comparing two Ontario hospitals. J Oncol Pharmacy Prac (abstract 22), doi:10.1177/1078155219834495.

Danese MD, Katz A, Cetin K, Chia V, Gleeson ML, Kelsh M, et al. 2019. Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data. Leuk Lymphoma 60(8):2015–2024.

Mease K. Managing immunogenicity in the absence of an ADA assay is no monkey business (case study). Presentation at 25^th annual Charles River Biotech Symposium, Carlsbad, CA, September 2019.

Nordyke RJ, Reichert H, Bylsma LC, Jackson JJ, Gage SM, Fryzek J, Roy-Chaudhury P, Lithgow T. 2019. Costs attributable to arteriovenous fistula and arteriovenous graft placements in hemodialysis patients with Medicare coverage. Am J Nephrol 50(4):320-328; doi: 10.1159/000502507.

Thompson CM, Fitch SE, Ring C, Rish W, Cullen JM, Haws LC. 2019. Development of an oral reference dose for the perfluorinated compound GenX. J Appl Toxicol 39:1267–1282.

Yoon M, Ring C, Van Landingham CB, Suh M, Song G, Antonijevic T, Gentry PR, Taylor MD, Keen AM, Andersen ME, Clewell JH. 2019. Assessing children’s exposure to manganese in drinking water using a PBPK model. Toxicol Appl Pharmacol 380(Oct 1):114695; doi: 10.1016/j.taap.2019.114695.

Fitch S, Goyak K, Green M, Grimm F, Wikoff D. 2019. Estrogen-mediated outcomes for alkylphenols via an adverse outcome pathway (AOP) construct. Open Science Framework, August.

Fergie J, Gonzales T, Jiang X, Fryzek J, Rizzo CP. Respiratory syncitial virus hospitalizations (RSVH) and all-cause bronchiolitis hospitalizations (BH) among 29-34 weeks gestational age (wGA) preterm infants before and after the 2014 American Academy of Pediatrics (AAP) immunoprophylaxis policy change using the Children’s Hospital Association’s Pediatric Health Information System (PHIS). Poster presentation at IDWeek, Washington, DC, October, 2019.

Röth A,  Fryzek J, Jiang X, Reichert H, Morales J, Broome CM. Seasonal patterns of thromboembolic events in cold agglutinin disease (CAD) in the United States. Presentation at 81st Annual Meeting of the Japanese Society of Hematology, Tokyo, Japan, October 2019.

Röth A, Fryzek J, Jiang X, Reichert H, Morales J, Broome CM. Seasonal patterns of anemia, hemolytic markers, healthcare resource utilization, and thromboembolic events in cold agglutinin disease. Presentation at German Society for Hematology and Medical Oncology, Berlin, Germany, October 2019.

Proctor D. Use of the latest science in cancer risk assessment for hexavalent chromium: Is it time to step away from the default regulatory approaches? Invited presentation to the International Union of Toxicology (IUTOX) / International Congress of Toxicology (ICT) meeting, Honolulu, HI, June 2019.

Fitch S, van de Ligt J, Payne L, Doepker C, Kleinman R, Handu D, Cohen SM, Anyangwe N, Wikoff D. 2019. Systematic map protocol: A systematic map of the use of acceptable daily intake (ADI) as a health-based benchmark in nutrition research studies that consider the safety of low-calorie sweeteners (LCS). Open Science Framework.